Koller P T, Bergmann S R
Department of Internal Medicine, Washington University School of Medicine, St. Louis, MO 63110.
Circ Res. 1989 Sep;65(3):838-46. doi: 10.1161/01.res.65.3.838.
The calcium-channel inhibiting agent, diltiazem, has been shown to enhance salvage of reperfused myocardium independent of effects on coronary blood flow or myocardial work. Because lipid peroxidation may be a mediator of reperfusion injury and modifiable by calcium-sensitive pathways, we evaluated the effects of diltiazem on the formation of malondialdehyde (MDA), a product of lipid peroxidation, in isolated rabbit hearts perfused with buffer under control conditions or after 60 minutes of ischemia with or without 3 minutes of reperfusion. Diltiazem (5 x 10(-7)M) reduced tissue MDA content in seven reperfused hearts compared with levels measured in 14 hearts reperfused without drug (1.54 +/- 1.09 [SD] compared with 3.57 +/- 1.88 nmol/g, p less than 0.05). Superoxide dismutase and catalase were ineffective in reducing tissue MDA content in reperfused hearts (n = 8; MDA concentration, 3.88 +/- 2.82 nmol/g) although they were effective in preventing lipid peroxidation in separate studies in which oxygen-centered free radicals were generated directly by an infusion of xanthine oxidase and hypoxanthine. These results suggest that the salutary effects of diltiazem in the setting of reperfusion may be mediated by reduction of lipid peroxidation at a locus not accessible to scavengers of oxygen-centered free radicals or by a mechanism not mediated by free radical pathways.
钙通道阻滞剂地尔硫䓬已被证明可增强再灌注心肌的挽救作用,且与对冠状动脉血流或心肌做功的影响无关。由于脂质过氧化可能是再灌注损伤的介质,并且可通过钙敏感途径进行调节,因此我们评估了地尔硫䓬对丙二醛(MDA,脂质过氧化产物)形成的影响,实验对象为在对照条件下或经历60分钟缺血(有无3分钟再灌注)后用缓冲液灌注的离体兔心。与14个未用药再灌注心脏所测水平相比,地尔硫䓬(5×10⁻⁷M)降低了7个再灌注心脏的组织MDA含量(分别为1.54±1.09[标准差]与3.57±1.88 nmol/g,p<0.05)。超氧化物歧化酶和过氧化氢酶在降低再灌注心脏的组织MDA含量方面无效(n = 8;MDA浓度为3.88±2.82 nmol/g),尽管在单独的研究中,当通过注入黄嘌呤氧化酶和次黄嘌呤直接产生以氧为中心的自由基时,它们能有效防止脂质过氧化。这些结果表明,地尔硫䓬在再灌注情况下的有益作用可能是通过减少脂质过氧化来介导的,其作用位点是氧中心自由基清除剂无法到达的,或者是通过一种不由自由基途径介导的机制。